首页> 外文OA文献 >Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures
【2h】

Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures

机译:FK 506和嘌呤生物合成抑制剂咪唑ribine或霉酚酸联合给药对人混合淋巴细胞培养物中淋巴细胞DNA合成和T细胞活化分子表达的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our objective was to obtain new information on the in vitro antilymphocytic action of the cytokine synthesis inhibitor FK 506 and the purine biosynthesis inhibitors mycophenolic acid (MPA; the active moiety of RS61443) and mizoribine (MZB) when used alone or in combination. When added at the initiation of six-day human mixed lymphocyte cultures (MLC), FK 506, MPA or MZB exhibited dose-dependent inhibition of T-lymphocyte DNA synthesis. FK 506, however, was 100-fold more potent than MPA, and 10000-fold more potent than MZB. Combination of FK 506 with either MPA or MZB, each at suboptional concentrations, produced no more than additive inhibitory effects on 3 H thymidine incorporation. Two-colour flow cytometric analysis of lymphocytes revealed that none of the drugs affected cell surface activation molecule expression (CD25 = IL-2R 55 kD α-chain, HLA-DR or CD71 = transferrin receptor [TR]) on allostimulated CD4 + or CD8 + cells harvested at three days of culture. By day six, however, all three agents, at levels which markedly inhibited proliferation, suppressed the expression of activation markers on both CD4 + and CD8 + cells. Also at day six, inhibition of activation molecule expression on CD4 + cells was achieved with the combination of FK 506 and either MPA or MZB at concentrations which, on their own, were ineffective. These data provide new, additional information on the in vitro antilymphocytic action of FK 506, MPA and MZB when used alone and in combination. © 1993.
机译:我们的目标是获得有关单独或组合使用时细胞因子合成抑制剂FK 506和嘌呤生物合成抑制剂霉酚酸(MPA; RS61443的活性部分)和咪唑啉碱(MZB)的体外抗淋巴细胞作用的新信息。在六天人类混合淋巴细胞培养(MLC)开始时添加时,FK 506,MPA或MZB表现出剂量依赖性的T淋巴细胞DNA合成抑制作用。然而,FK 506的效力是MPA的100倍,效力是MZB的10000倍。 FK 506与MPA或MZB的组合(各自处于亚可选浓度)对3 H胸腺嘧啶核苷的掺入只产生累加的抑制作用。淋巴细胞的双色流式细胞分析表明,没有一种药物会影响同化刺激的CD4 +或CD8上的细胞表面活化分子表达(CD25 = IL-2R 55 kDα链,HLA-DR或CD71 =转铁蛋白受体[TR])。培养三天后收获的+细胞。然而,到第六天,所有三种试剂均以显着抑制增殖的水平抑制了CD4 +和CD8 +细胞上激活标记的表达。同样在第6天,用FK 506和MPA或MZB以其自身无效的浓度组合实现了对CD4 +细胞上活化分子表达的抑制。这些数据提供了有关FK 506,MPA和MZB单独或组合使用时体外抗淋巴细胞作用的新信息。 ©1993。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号